Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02455804 · ClinicalTrials.gov registry record · NA

NIRTRAKS Post-Market Study (NIRTRAKS)

A NA study, sponsored by Medinol.

Completed
Registry status
NA
Development phase
65
Enrollment target

NCT02455804: Completed NA study, sponsored by Medinol.

NCT02455804 is a NA study that has completed, run by Medinol. The registered enrollment target is 65 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02455804, a NA study, has completed, sponsored by Medinol.

COMPLETED
Registry status
NA
Development phase
65 participants
Enrollment target

Study Summary

This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.

Primary Outcome

The primary endpoint in this study was TVF (Target Vessel Failure) defined as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods within 3 years post-procedure.

Interventions

  • DEVICE Stenting procedure

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2016-01-08
Est. Completion 2020-01-14
Phase NA
Medinol

4 total trials

What the finished NCT02455804 record still lists

NCT02455804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Stenting procedure is the first listed.

NCT02455804 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02455804 about?

NCT02455804 is a clinical study titled "NIRTRAKS Post-Market Study (NIRTRAKS)". This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting pr...

What is the current status of trial NCT02455804?

This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2016-01-08. Estimated completion is 2020-01-14.

What interventions are being tested in trial NCT02455804?

The interventions under investigation include: Stenting procedure (DEVICE).

Who is sponsoring clinical trial NCT02455804?

This trial is sponsored by Medinol, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02455804's enrollment target sits among peer trials

65 1144th of 2000 higher than 854 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02455804, the US trial registry maintained by the National Library of Medicine. NCT02455804 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.